Pharmaceutical manufacturers of Ranitidine

TAPI stands as the primary global provider of active pharmaceutical ingredients (APIs). With the most extensive range of over 370 high-caliber API products in the industry, we cater to almost 1,000 clients across more than 100 nations. Operating as an independent division under Teva Pharmaceutical Industries, our legacy in the generic API sector spans over 80 years. Situated in close proximity to Tel Aviv, Israel, TAPI boasts a workforce of over 5,000 professionals spread across 19 facilities worldwide. Our cutting-edge manufacturing plants are situated in Italy, Hungary, the Czech Republic, Croatia, Israel, India, China, Mexico, and several other locations.

CordenPharma International, an all-encompassing CDMO for the worldwide market. Established as the global pharmaceutical service & production platform of International Chemical Investors Group in 2006, CordenPharma serves as your all-encompassing ally in the Contract Development & Manufacturing (CDMO) of APIs, Drug Products, and associated Packaging Services. With an expanding network of cGMP facilities throughout Europe and the US structured under five Technology Platforms – Peptides, Lipids & Carbohydrates - Highly Potent & Oncology - Injectables - Small Molecules - Antibiotics – CordenPharma specialists interpret intricate processes, concepts and ventures at any phase.

Wockhardt UK (WUK) operates as a diverse pharmaceutical company, serving as a significant provider of healthcare products to the NHS through hospitals, multiple retail pharmacy chains, and wholesalers. It is currently experiencing an exciting period with thriving export and contract manufacturing divisions. Leveraging the global strength, research base, and impressive product pipeline of its parent company, Wockhardt UK is well-positioned for future growth.

CSPC Pharmaceutical Group Limited ("CSPC") (Stock code: 1093.HK) is a leading pharmaceutical group in China. The Company has been listed on the Main Board of the Hong Kong Stock Exchange since 1994 and became a constituent stock of the Hang Sang Index in 2018 (the 1st constituent stock in the pharmaceutical sector since launch of the index). CSPC is currently also a constituent stock of the "Hang Seng Composite Index", "Hang Seng Healthcare Index", "Hang Seng SCHK Mainland China Healthcare Index", "Hang Seng Stock Connect Hong Kong Index", "Hang Seng China (Hong Kong-listed) 100 Index" and "Hang Seng China Enterprises Index". CSPC mainly owns two business segments of finished drugs and bulk drugs, with innovative drugs as the core development strategy. CSPC currently has a strong product portfolio in the therapeutic areas of nervous system disease, oncology, anti-infective and cardiovascular disease. Of which "NBP", "Domeisu", "Jinyouli", "Keaili" and "Xuanning" are the most popular innovative drug products in China. Bulk drug products include vitamin C, antibiotics and caffeine series. The manufacturing facilities of CSPC are mainly located in Shijiazhuang City, Hebei Province, China. CSPC has a international R&D team with R&D bases in Shijiazhuang, Shanghai, Beijing and the United States, focusing on the discovery, research and development of small molecule targeted drugs, nano-drugs, monoclonal antibody drugs, bispecific antibody drugs, antibody-drug conjugates and biological drugs in the immune field.

Established in 1984, Neuland Laboratories Limited is a publicly traded company based in Hyderabad, India. The organization offers solutions throughout the entire range of the pharmaceutical industry's chemical needs, from synthesizing library compounds to providing NCEs and advanced intermediates at different stages in the clinical life cycle, as well as for commercial launch. Neuland's specialty lies in the production of APIs and advanced intermediates from its facilities approved by the USFDA. Its primary expertise is the application of effective process chemistry to manufacturing in a compliant regulatory setting.

Solara is an API manufacturer focused on research and customer satisfaction, operating in over 75 countries. They specialize in producing APIs for niche therapeutic categories, including complex products like polymer-based APIs and injectable APIs. The company has a team of experienced scientists supported by 6 manufacturing facilities and 2 R&D centers. Additionally, Solara offers Contract Research and Manufacturing Services (CRAMS) from discovery to late phase commercial manufacturing. Solara Active Pharma Sciences, with roots in Strides Shasun Ltd. and Sequent Scientific Ltd., is committed to providing value-based products while prioritizing customer needs. The company has 140+ scientists working at 2 R&D centers and 4 API manufacturing facilities, all with global approvals and 2 dedicated R&D facilities.

SMS Lifesciences India Limited, headquartered in Hyderabad, India, is a research-driven company with over three decades of experience. It is a public listed leading API manufacturer, supplying to major generic and innovator firms. With a focus on APIs, the company operates four state-of-the-art facilities and provides quality alternative manufacturing solutions to multinational companies for their contract research and manufacturing needs. The company has multiple manufacturing facilities supporting a wide range and capacity of APIs and Intermediates.

Aarti Drugs Ltd (ADL) is a part of the Aarti Group of Industries, which has a total worth of USD 500 million. It was established in 1984 and has since developed a strong presence in the fields of Anti-diarrhea and Anti-inflammatory therapeutic groups. The company's manufacturing facilities are located in Tarapur and Sarigam, where it produces a variety of medicines including Vitamins, Anti-arthritis, Anti-fungal, Antibiotics, ACE inhibitors, anti-diabetic, anti-cholinergic, sedatives, and anti-depressant drugs. Over the years, ADL has successfully carved a niche for itself and is now planning to increase its production capacity.

Bringing 86 years of expertise, UQUIFA'S operational approach is built on a fusion of a high-quality production platform and a proven history of service and dependability. UQUIFA specializes in the production of Active Pharmaceutical Ingredients (APIs), Intermediates, and RSM's for the pharmaceutical and animal health sectors on a global scale. The organization runs 2 production facilities (located in Spain and Mexico) with stringent compliance to all regulatory standards. These facilities operate under cGMP conditions and have undergone evaluation and endorsement from prominent global pharmaceutical companies.

We, at TIEFENBACHER GROUP, are driven by a deep sense of purpose: we are pioneering healthcare to improve patients’ lives around the world. We believe that the access to affordable high quality-healthcare is a human right. We always challenge the status quo to be one step ahead – in terms of business models as well as concrete products and services. This entrepreneurial spirit is the driving force of making high-quality pharmaceuticals more affordable, more available, and better than before. 100% family owned since 1963, we are a purpose-driven healthcare company providing best-in-class solutions throughout the entire pharmaceutical value chain. From initial idea to market access: We distribute raw materials and develop, manufacture, and register finished dosage forms like tablets, capsules, powders, drops, and patches as well as medical devices. This broad competence enables us to pioneer healthcare holistically as we can connect ideas and expertise to create novel healthcare solutions. By working together as TIEFENBACHER GROUP, in agile collaboration and cross-functional structures, we tap into our full potential and stay at the forefront of our field.

The Virchow Group, situated in the city of Hyderabad, India, is a producer of Active Pharmaceutical Ingredients and finalized formulations. This renowned organization is the largest global manufacturer of Sulfamethoxazole and Ranitidine APIs and has obtained cGMP approval from the US FDA as well as CEP certification from EDQM for these APIs. Additionally, the Virchow Group is a prominent manufacturer of Cephalosporins APIs such as Cefixime, Cefdinir, Cefprozil, Cefpodoxime Proxetil, Cefuroxime Axetil, and Cefditoren Pivoxil, along with other Sulfa drugs like Sulfanilamide and Sulfapyridine, as well as intermediates including Cis-Lactam, GCLE, 7-AVNA, and 7-APCA. They also produce finished dosages.

SCL was incorporated on December 20, 1993, as a Private Limited Company. Initially, it manufactured intermediates. On July 1, 1997, the company became a Public Limited Company and adopted its current name. In 2004, SCL established a new API manufacturing facility. Today, it offers a wide range of APIs and advanced intermediates in various therapeutic segments such as NSAIDs, cardiology, anti-cholinergic, CNS, anti-filarials, and anthelmintics, among others, to its customers. We are based in Panchkula, near Chandigarh, with two manufacturing facilities in Derabassi, Mohali (Punjab), for intermediates and APIs. The marketing office is located in Delhi NCR. We have acquired 22 acres of land for expanding facilities near the current site.

MAPRIMED SA is an Argentine company that develops and produces active ingredients for the global pharmaceutical industry.

Kores India Limited, Pharmaceuticals & Chemicals Division, is a top producer of APIs and Pharmaceutical Intermediates